Cullinan Therapeutics Advances Velinotamig into Global Clinical Development
The company said it received U.S. FDA clearance for an investigational new drug application, allowing global clinical development of velinotamig for autoimmune cytopenias.
Related stories
Granite Construction Reports Quarterly Results
Granite Construction reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 04:31 PM UTC
Perrigo Announces Quarterly Dividend of $0.29 Per Share
Perrigo announced a quarterly dividend of $0.29 per share.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
Euro Stoxx Index Rises 0.73%
Euro zone blue chips are up 0.64%.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
FTSE 100 rises 0.29%; DAX gains 1.36%
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
France's CAC 40 rises 1.12%; Spain's IBEX falls 0.27%
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
US session market picture: S&P 500 -0.4%, Nasdaq 100 -1.37%; EUR/USD +0.06%, WTI -1.52%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.4 percent, Nasdaq futures is down 1.37 percent, Dow futures is down 0.44 percent and Russell futures is up 1.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC